Shire plc today announced that the FDA has approved the prescription
medication Vyvanse (lisdexamfetamine dimesylate) Capsules CII for the treatment
of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to
17. The approval is based on study data demonstrating that Vyvanse improved ADHD
symptoms compared to placebo in adolescents with ADHD. Vyvanse is also
indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.
“This adolescent indication for Vyvanse is good news
for kids in this age group diagnosed with ADHD and their caregivers as it
offers an additional treatment option to help them manage their symptoms,”
said Mike Yasick, Senior Vice President of Shire’s ADHD Business. “The approval
of Vyvanse for children and adults – and now for adolescents – underscores
Shire’s commitment to helping ADHD patients and their families.”
